A new analysis, designed to shed light on the benefits of SGLT2 inhibition in patients who have heart failure with preserved ejection fraction (HFpEF), shows that dapagliflozin (Farxiga; AstraZeneca) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback